DGAP-Adhoc: Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE

2020. október 13., kedd, 00:34





DGAP-Ad-hoc: Evotec SE / Key word(s): Capital Increase


Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE


13-Oct-2020 / 00:34 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Disclosure of an inside information according to Article 17 MAR

Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE

Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) today announced that it resolved on a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S.



In this private capital increase, Mubadala Investment Company will invest € 200 million to subscribe 9,182,652 Evotec shares at a share price of € 21.7802 per share representing approx. 5.6% of outstanding shares. Evotec gains with Mubadala Investment Company a new long-term strategic oriented shareholder with extensive experience and expertise in the biotech industry. Evotec"s existing long-term shareholder Novo Holdings A/S will invest € 50 million to subscribe 2,295,663 shares of Evotec at a same share price to reinforce its ownership at approx. 11.0%, to secure financial flexibility for the Company.



The placement was made at 2.5% discount to the five-day volume weighted average price ("VWAP") of € 22.3387 prior to the Xetra closing auction on 12th October 2020. After the registration of the capital increase in the commercial register, the share capital of the Company will increase to € 163,375,808 or 163,375,808 ordinary bearer shares.



While maintaining the business outlook 2020 unchanged, Evotec will be using the proceeds from the capital increase to pursue its unique strategy to become the global leading platform company for the modality-agnostic development of innovative first-in-class and best-in-class therapeutic approaches resulting in a very large co-owned pipeline.



 






Information and Explanation of the Issuer to this News:

Contact: 

Dr Werner Lanthaler, Chief Executive Officer

Evotec SE

Manfred Eigen Campus

Essener Bogen 7

22419 Hamburg, Germany

Phone: +49.(0)40.560 81-242

Email: werner.lanthaler@evotec.com

 





13-Oct-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de





























Language: English
Company: Evotec SE

Manfred Eigen Campus / Essener Bogen 7

22419 Hamburg

Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1140411





 
End of Announcement DGAP News Service




1140411  13-Oct-2020 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=1140411&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.

Közzétételek - archívum